Bimatoprost Clinical Trials

Size	Price	Qty
10mg	USD 370
50mg	USD 897

Clinical Trials

Numerous clinical trials evaluate the efficacy, safety, and pharmacokinetic profiles of bimatoprost across Early Phase 1 through Phase 4 studies. While primarily targeting open-angle glaucoma and ocular hypertension, investigations also extend to androgenetic alopecia, healthy volunteers, and breast cancer. Sponsored by leading pharmaceutical entities including Allergan, AbbVie, and Laboratoires Thea alongside academic centers like Duke University, these trials exhibit varied recruitment statuses ranging from active and recruiting to completed and terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03708627	RECRUITING	Graves Ophthalmopathy	Johns Hopkins University	2017-11-01	EARLY_PHASE1
NCT07218796	RECRUITING	Cataract; Glaucoma; Ocular Hypertension	SpyGlass Pharma, Inc.	2025-10-28	PHASE3
NCT07218783	RECRUITING	Cataract; Glaucoma; Ocular Hypertension	SpyGlass Pharma, Inc.	2025-10-15	PHASE3
NCT07217678	RECRUITING	Glaucoma; Open-Angle Glaucoma; Ocular Hypertension; Glaucoma Suspect	University of Miami	2026-02-09	PHASE4
NCT07661329	RECRUITING	Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OH)	YS Life Science Co., Ltd.	2026-06-02	PHASE3
NCT07641296	NOT_YET_RECRUITING	Glaucoma; Ocular Hypertension	SpyGlass Pharma, Inc.	2026-07-31	PHASE1
NCT03891446	COMPLETED	Open-Angle Glaucoma; Ocular Hypertension	AbbVie	2019-03-27	PHASE3
NCT03850782	COMPLETED	Open-Angle Glaucoma; Ocular Hypertension	AbbVie	2019-02-28	PHASE3
NCT06267274	UNKNOWN	Open-angle Glaucoma; Ocular Hypertension	Amneal Pharmaceuticals, LLC	2024-04-01	PHASE1
NCT06120842	ACTIVE_NOT_RECRUITING	Cataract; Glaucoma; Ocular Hypertension	SpyGlass Pharma, Inc.	2023-10-13	PHASE1; PHASE2
NCT06122090	UNKNOWN	Scars; Hypopigmented Scar; Hypopigmented Skin; Burn Scar; Scarring; Cicatrix, Hypertrophic; Cicatrix; Pigmentation Disorder; Burns Laser	Medstar Health Research Institute	2023-07-18	PHASE2
NCT06761313	ACTIVE_NOT_RECRUITING	Glaucoma; Quality of Life (QOL)	Federal University of São Paulo	2021-03-01	PHASE4
NCT02390284	TERMINATED	Glaucoma	University of Miami	2015-09	PHASE3
NCT06369077	TERMINATED	Glaucoma, Open-Angle; Glaucoma; Drugs	CT Glaucoma Associates	2024-04-22	PHASE4
NCT05397600	COMPLETED	Glaucoma; Ocular Hypertension	Laboratoires Thea	2022-06-22	PHASE3
NCT05335122	COMPLETED	Open Angle Glaucoma; Ocular Hypertension	Ocular Therapeutix, Inc.	2022-03-16	PHASE2
NCT04898387	COMPLETED	Ocular Hypertension Glaucoma	Laboratoires Thea	2021-03-26	PHASE3
NCT05729594	COMPLETED	Healthy Volunteers	Laboratoires Thea	2023-02-27	PHASE1
NCT05729594	Completed	Healthy Volunteers	Laboratoires Thea	2023-02-27	Phase 1
NCT07154797	COMPLETED	Cataract; Ocular Hypertension; Glaucoma	SpyGlass Pharma, Inc.	2022-04-21
NCT05401357	RECRUITING	Glaucoma, Open-Angle; Ocular Hypertension	Amneal Pharmaceuticals, LLC	2022-06-29	PHASE3
NCT04890106	COMPLETED	Glaucoma, Open-Angle	Mankind Pharma Limited	2021-10-02	PHASE3
NCT04981886	UNKNOWN	Normal Tension Glaucoma	Salus University	2021-08	PHASE4
NCT04738149	COMPLETED	Vitiligo	Medical University of South Carolina	2021-11-02	EARLY_PHASE1
NCT04285580	COMPLETED	Open-Angle Glaucoma; Ocular Hypertension	AbbVie	2020-06-11	PHASE3
NCT02507687	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	AbbVie	2015-08-27	PHASE3
NCT04380025	UNKNOWN	Glaucoma	University of Puerto Rico	2020-05-15
NCT04647214	Recruiting	Open-angle Glaucoma\|Ocular Hypertension	Allergan	2021-03-03	--
NCT03825380	COMPLETED	Ocular Hypertension; Glaucoma	Laboratoires Thea	2018-11-23	PHASE3
NCT05600673	COMPLETED	Alopecia Areata	Ahmed Hassan Nouh MD	2019-01-01	PHASE1; PHASE2
NCT02636946	COMPLETED	Glaucoma; Open-Angle Ocular Hypertension	Allergan	2016-02-24	PHASE3
NCT03284853	COMPLETED	Open Angle Glaucoma; Ocular Hypertension	Aerie Pharmaceuticals	2017-09-05	PHASE3
NCT04285580	Completed	Open-Angle Glaucoma\|Ocular Hypertension	AbbVie	2020-06-11	Phase 3
NCT03487042	UNKNOWN	Generalized Vitiligo	Assiut University	2018-05	PHASE4
NCT03927443	WITHDRAWN	Open Angle Glaucoma; Ocular Hypertension	Sun Pharmaceutical Industries Limited	2019-06-10	PHASE3
NCT03419715	UNKNOWN	Migraine Disorders; Headache Disorders	Manistee Partners	2018-01-05	PHASE2
NCT03891446	Enrolling by invitation	Open-Angle Glaucoma\|Ocular Hypertension	AbbVie	2019-03-27	Phase 3
NCT02250651	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2014-12-15	PHASE3
NCT02863705	COMPLETED	Glaucoma, Open-Angle; Normal Tension Glaucoma	Allergan	2016-07-05	PHASE4
NCT02571712	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2015-11-10	PHASE4
NCT02247804	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2014-12-15	PHASE3
NCT00999557	WITHDRAWN	Alopecia; Breast Cancer	Jonsson Comprehensive Cancer Center	2016-01
NCT02471105	UNKNOWN	Ocular Hypertension; Glaucoma	Universitaire Ziekenhuizen KU Leuven	2015-09	PHASE4
NCT02155049	COMPLETED	Thyroid Associated Ophthalmopathies	Rabin Medical Center	2014-11	PHASE3
NCT02830776	COMPLETED	Dermatochalasis	Tulane University	2016-11	EARLY_PHASE1
NCT02676310	TERMINATED	Alopecia; Alopecia, Androgenetic; Baldness	Allergan	2016-03	PHASE1
NCT02742649	COMPLETED	Open-Angle Glaucoma; Ocular Hypertension	ForSight Vision5, Inc.	2016-04-30	PHASE1; PHASE2
NCT01298700	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2011-05-31	PHASE4
NCT02848300	COMPLETED	Androgenetic Alopecia	Allergan	2016-07	PHASE1
NCT02537015	COMPLETED	Primary Open-Angle Glaucoma; Ocular Hypertension	ForSight Vision5, Inc.	2015-08-10	PHASE2
NCT01157364	COMPLETED	Open-Angle Glaucoma; Ocular Hypertension	Allergan	2010-09-23	PHASE1; PHASE2
NCT02448043	COMPLETED	Nail Growth Cessation; Intraocular Pressure	Northwestern University	2015-06-04
NCT02059655	COMPLETED	Graves' Ophthalmopathy	Cardiff University	2014-11	PHASE4
NCT02143843	COMPLETED	Primary Open-Angle Glaucoma; Ocular Hypertension	ForSight Vision5, Inc.	2014-06-05	PHASE2
NCT02358369	COMPLETED	Primary Open-Angle Glaucoma; Ocular Hypertension	ForSight Vision5, Inc.	2015-01-19	PHASE2
NCT02176356	COMPLETED	Facial Rhytides; Crow's Feet Lines; Glabellar Lines; Nasolabial Fold	Allergan	2014-06-30	PHASE4
NCT02444767	COMPLETED	Healthy Volunteers	ForSight Vision5, Inc.	2015-03	PHASE1
NCT01975714	COMPLETED	Glaucoma; Ocular Hypertension	Association for Innovation and Biomedical Research on Light and Image	2013-10	PHASE4
NCT03966560	COMPLETED	Glaucoma, Open-Angle	Afyon Kocatepe University Hospital	2014-01	PHASE4
NCT02097719	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2014-05	PHASE4
NCT01426113	TERMINATED	Glaucoma	Allergan	2011-09	PHASE3
NCT01881126	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2013-06	PHASE4
NCT01915940	COMPLETED	Primary Open-Angle Glaucoma; Ocular Hypertension	ForSight Vision5, Inc.	2013-10-23	PHASE2
NCT01904721	COMPLETED	Alopecia; Alopecia, Androgenetic; Baldness	Allergan	2013-08	PHASE2
NCT01217606	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2011-01	PHASE3
NCT01891487	COMPLETED	Hypotrichosis	ATS Clinical Research	2013-05	PHASE4
NCT01664039	COMPLETED	Glaucoma; Ocular Hypertension	Alcon Research	2012-09	PHASE4
NCT01830140	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2013-07	PHASE3
NCT01698554	COMPLETED	Idiopathic Eyelash Hypotrichosis	Allergan	2012-11	PHASE3
NCT01765764	COMPLETED	Eyebrow Hypotrichosis	Allergan	2013-03-13	PHASE3
NCT01863953	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2013-06	PHASE2
NCT01241240	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2011-03	PHASE3
NCT01547598	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2011-12	PHASE4
NCT01493427	COMPLETED	Open-Angle Glaucoma; Ocular Hypertension	Alcon Research	2011-12	PHASE4
NCT01594970	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2012-03	PHASE4
NCT02020512	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2011-07	PHASE4
NCT01023841	COMPLETED	Eyelash Hypotrichosis; Alopecia Areata	Allergan	2010-06-01	PHASE4
NCT01327599	COMPLETED	Open-Angle Glaucoma; Ocular Hypertension; Pigment Dispersion Glaucoma	Alcon Research	2011-08	PHASE4
NCT01271686	COMPLETED	Intraocular Pressure; Glaucoma; Ocular Hypertension	University of California, San Diego	2011-01	PHASE4
NCT01525173	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2012-01	PHASE4
NCT01325337	COMPLETED	Alopecia; Alopecia, Androgenetic; Baldness	Allergan	2011-06	PHASE2
NCT01216943	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2010-11	PHASE3
NCT01325350	COMPLETED	Alopecia; Baldness	Allergan	2011-06	PHASE2
NCT01978015	COMPLETED	Uveitis, Anterior; Cystoid Macular Edema	University of Campinas, Brazil	2011-10	PHASE4
NCT01464424	COMPLETED	Glaucoma; Ocular Hypertension; Open-Angle Glaucoma	Alcon Research	2011-10	PHASE4
NCT01391286	COMPLETED	Eyelash Hypotrichosis	Allergan	2011-07-01	PHASE3
NCT01391273	COMPLETED	Eyelash Hypotrichosis	Allergan	2011-07-01	PHASE3
NCT01448525	COMPLETED	Hypotrichosis	Allergan	2011-10	PHASE4
NCT01387906	COMPLETED	Hypotrichosis	Kenneth Beer	2011-03	PHASE4
NCT01243567	COMPLETED	Glaucoma, Open-Angle	Allergan	2010-06-01	PHASE4
NCT01177098	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2010-10	PHASE3
NCT01361841	UNKNOWN	Ocular Hypertension; Primary Glaucoma	Centre de recherche du Centre hospitalier universitaire de Sherbrooke	2009-01
NCT01542710	COMPLETED	Glaucoma	Kasr El Aini Hospital	2011-01
NCT01291108	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2011-04	PHASE2
NCT01253902	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2010-12	PHASE4
NCT02061683	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2010-04-19	PHASE4
NCT01110499	COMPLETED	Ocular Hypertension; Primary Open-Angle Glaucoma	Allergan	2010-06	PHASE2
NCT02170662	COMPLETED	Male Pattern Hair Loss; Androgenetic Alopecia	Duke University	2009-11	PHASE2
NCT01099774	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2010-05-01	PHASE3
NCT00705757	COMPLETED	Glaucoma; Application Site Pigmentation Changes	Summa Health System	2008-03	PHASE4
NCT01833741	COMPLETED	Glaucoma, Primary Open Angle; Ocular Hypertension	Allergan	2009-12	PHASE4
NCT01448837	COMPLETED	Glaucoma	Aristotle University Of Thessaloniki	2010-04	PHASE4
NCT01230736	COMPLETED	Glaucoma	Alcon Research	2010-10	PHASE4
NCT01189279	COMPLETED	Alopecia; Alopecia, Androgenetic; Baldness	Allergan	2010-10	PHASE1
NCT00907426	COMPLETED	Hypotrichosis	Allergan	2009-08	PHASE3
NCT00941096	COMPLETED	Glaucoma; Ocular Hypertension	Larissa University Hospital	2009-07	PHASE4
NCT01202513	WITHDRAWN	Vitiligo; Repigmentation	Gian Sagar Medical College and Hospital	2010-08	PHASE4
NCT01068964	COMPLETED	Open-angle Glaucoma; Ocular Hypertension	Allergan	2010-02-01
NCT01170884	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2009-12	PHASE4
NCT00958035	COMPLETED	Hypotrichosis	Allergan	2009-11	PHASE4
NCT01064882	COMPLETED	Eyelash Hypotrichosis	Allergan	2010-03	PHASE2
NCT01229423	COMPLETED	Eyelash Hypotrichosis	Allergan	2009-11	PHASE4
NCT01001195	COMPLETED	Glaucoma, Open-Angle; Ocular Hypertension	Allergan	2009-11	PHASE2
NCT01016691	COMPLETED	Open-angle Glaucoma; Ocular Hypertension	Vistakon Pharmaceuticals	2009-10	PHASE2
NCT00809848	COMPLETED	Ocular Hypertension; Glaucoma	Allergan	2009-02	PHASE1; PHASE2
NCT00541242	COMPLETED	Ocular Hypertension; Glaucoma	Allergan	2007-12	PHASE4
NCT00539526	COMPLETED	Open Angle Glaucoma; Ocular Hypertension	Allergan	2007-09	PHASE4
NCT00773136	COMPLETED	Hypertrichosis	University of Miami	2008-02
NCT00538304	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2007-11	PHASE2
NCT00486486	COMPLETED	Glaucoma	Aristotle University Of Thessaloniki	2007-03	PHASE4
NCT00693420	COMPLETED	Eyelashes	Allergan	2007-04	PHASE3
NCT00440011	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2006-08	PHASE4
NCT01200251	COMPLETED	Madarosis; Hypotrichosis	Duke University	2007-02	PHASE3
NCT00300443	COMPLETED	Ocular Hypertension	Allergan	2005-12	PHASE2; PHASE3
NCT00187577	COMPLETED	Alopecia Areata	University of California, San Francisco	2005-06
NCT00652496	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2005-01	PHASE2
NCT02154217	COMPLETED	Glaucoma	University of Milan		PHASE3
NCT00332059	COMPLETED	Ocular Hypertension	Allergan	2003-05	PHASE3
NCT00651859	COMPLETED	Glaucoma; Ocular Hypertension	Allergan	2002-11	PHASE2
NCT01655758	COMPLETED	Ocular Hypertension	University of Parma	2002-01	PHASE4
NCT00332072	COMPLETED	Ocular Hypertension	Allergan	2001-08	PHASE3
NCT00332540	COMPLETED	Ocular Hypertension	Allergan	2001-08	PHASE3
NCT00847483	COMPLETED	Glaucoma; Ocular Hypertension	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	2002-01	PHASE4
NCT00347841	COMPLETED	Glaucoma	Innovative Medical		PHASE4
NCT00348023	COMPLETED	Glaucoma	Innovative Medical		PHASE4
NCT00329095	COMPLETED	Glaucoma; Ocular Hypertension	Robin, Alan L., M.D.	2005-12	PHASE4
NCT00347802	COMPLETED	Glaucoma	Innovative Medical		PHASE4
NCT00355446	COMPLETED	Cataract	Indiana University	2001-07	PHASE4
NCT00567788	UNKNOWN	Glaucoma, Angle-Closure	Singapore National Eye Centre	2006-07
NCT00348062	COMPLETED	Glaucoma	Innovative Medical		PHASE4
NCT00273455	COMPLETED	Open-Angle Glaucoma	Pharmaceutical Research Network	2006-01	PHASE4

(data from https://clinicaltrials.gov, updated on 2026-07-16)

Check the Bimatoprost product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Bimatoprost acts as a synthetic prostamide analog that selectively binds to prostamide receptors, modulating intracellular signaling pathways to enhance uveoscleral and trabecular outflow of aqueous humor. This increased fluid drainage effectively reduces elevated intraocular pressure, providing a direct therapeutic mechanism for managing open-angle glaucoma and ocular hypertension as evaluated in clinical trials.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).